Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

prolymphocytic leukemia (PLL) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

prolymphocytic leukemia

MONDO:0001023

Also known as:PLLprolymphocytic leukaemia (B or T)prolymphocytic leukaemia (B or T-cell)

Find Clinical TrialsTrials

Overview

A mature B- or T- cell leukemia with progressive clinical course. It is characterized by the presence of medium-sized lymphocytes with visible nucleoli (prolymphocytes) in the peripheral blood, bone marrow, and spleen.

TreatmentsNo approved treatments · 1 in pipeline

Clinical Trials25 registered · 11 recruiting

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for prolymphocytic leukemia. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for prolymphocytic leukemia, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for prolymphocytic leukemia. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

25 clinical trials registered, 11 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 7 PHASE2, 11 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT01137825](https://clinicaltrials.gov/study/NCT01137825)

Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 8:32 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

GARD

Genetic and Rare Diseases Info Center

GARD:11965

Questions for Your Care Team

→Are any of the 25 active clinical trials a good fit for my situation?
→What is the current development status of blinatumomab, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	38	47%
Laboratory research	17	21%
Clinical study results	13	16%
Research summaries	5	6%
New treatment approaches	5	6%
Disease patterns and progression	2	2%
Other research	1	1%

prolymphocytic leukemia

Overview

Treatment

Orphan Drug Designations

Research Landscape

Medical References

External Resources

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications